Lifeway Foods

Lifeway does $187M in annual sales, has $0M of long-term debt, and still trades at 32.8 times earnings.

If you own Lifeway, you own a real growth story with a very full price tag.

lway

consumer small cap updated jan 2, 2026
$24.27
market cap ~$318M · 52-week range $20–$34
xvary composite: 47 / 100 · below average
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
Lifeway sells kefir, cheese, yogurt, and other cultured dairy products to make fermented milk a repeat purchase.
how it gets paid
Last year Lifeway Foods made $187M in revenue. drinkable kefir was the main engine at $127.2M, or 68% of sales.
what just happened
Lifeway's latest reported quarter showed $0.23 EPS, with gross margin at 27.3% and the full business running at $187M in trailing revenue.
At a glance
B balance sheet — gets the job done, barely
35/100 earnings predictability — expect surprises
32.8x trailing p/e — you're paying up for this one
12.6% return on capital — nothing to write home about
$0.60 fy2024 eps est
xvary composite: 47/100 — below average
What they do
Lifeway sells kefir, cheese, yogurt, and other cultured dairy products to make fermented milk a repeat purchase.
Kefir is a niche until it becomes your breakfast, and then you keep grabbing the same bottle. Lifeway turned that habit into $187M of annual sales with just 291 employees, or about $643,000 of revenue per employee. Zero long-term debt → no balance-sheet strain → the company gets time to keep defending shelf space and brand loyalty.
consumer microcap branded-food dairy probiotics
How they make money
$187M annual revenue
drinkable kefir
$127.2M
european-style soft cheeses
$22.4M
cream and other
$15.0M
drinkable yogurt
$11.2M
ProBugs kids kefir
$7.5M
other dairy
$3.7M
The products that matter
core fermented dairy beverage
Drinkable Kefir
~$168M · roughly 90% of revenue
It's the product that built nearly all of the current $187M revenue base, which means the old business is still carrying the story.
40-year core
new dairy adjacencies
Probiotic Kefir Butter
part of ~10% new-product mix
It matters because management wants new products to jump from roughly 10% to 30% of revenue by the end of 2026.
pivot test
protein-focused line extension
Muscle Mates
growth category bet
This line is another attempt to make the next $19M of revenue look different from the last $168M.
share grab
Key numbers
32.8x
trailing p/e
Price-to-earnings → how many dollars you pay for $1 of profit → you are paying a premium for a company with $187M of revenue.
9.2%
operating margin
Operating margin → profit after operating costs → Lifeway keeps about $9.20 from every $100 of sales before interest and taxes.
12.6%
return on capital
Return on capital → profit generated from the money used in the business → Lifeway earns about 12.6 cents for each dollar invested.
$0M
long-term debt
Long-term debt → borrowed money due over years → Lifeway has none, which matters when small food companies hit rough patches.
Financial health
B
strength
  • balance sheet grade B — adequate — nothing special
  • risk rank 3 — safer than 50% of stocks
  • price stability 5 / 100
  • long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market

Return history isn't available for LWAY right now.

same standard. no invented return math.

source: institutional data · return history unavailable
What just happened
beat estimates
Lifeway's latest reported quarter showed $0.23 EPS, with gross margin at 27.3% and the full business running at $187M in trailing revenue.
EPS stepped up from $0.21 in Q2 2023 to $0.23 in the latest reported quarter from the quarterly history. Gross margin was 27.3% in EDGAR, which tells you the real story: this is a small dairy company finally keeping more of each sales dollar.
$187M
revenue
$0.23
eps
27.3%
gross margin
the number that mattered
27.3% gross margin matters most because margin → money left after making the product → so what: it decides whether $187M in sales turns into real earnings.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

The #1 risk is missing the jump from roughly 10% to 30% of revenue from new products.

!
high
product mix pivot misses
The company wants new products at 30% of revenue by end of 2026, up from roughly 10% now. If it only gets halfway there, the market is left paying 32.8x earnings for a business that still looks mostly the same.
The company wants new products at 30% of revenue by end of 2026, up from roughly 10% now. If it only gets halfway there, the market is left paying 32.8x earnings for a business that still looks mostly the same.
∘
med
new lines pressure margin
Gross margin is 27.3%. If butter, protein, and other launches come in below the core kefir economics, growth can rise while profitability stands still. That's how a "growth" story becomes a grocery stock in a hurry.
Gross margin is 27.3%. If butter, protein, and other launches come in below the core kefir economics, growth can rise while profitability stands still. That's how a "growth" story becomes a grocery stock in a hurry.
∘
med
category concentration
About 90% of revenue still comes from drinkable kefir. That focus helps brand identity, but it also means one aisle still does most of the heavy lifting.
About 90% of revenue still comes from drinkable kefir. That focus helps brand identity, but it also means one aisle still does most of the heavy lifting.
∘
med
concentrated governance
Governance influence is concentrated, which can matter more at a $318M company than it does at a megacap. If strategy wobbles, minority shareholders have fewer ways to steer the wheel.
Governance influence is concentrated, which can matter more at a $318M company than it does at a megacap. If strategy wobbles, minority shareholders have fewer ways to steer the wheel.
A failed pivot leaves you with a niche dairy company on $187M of revenue, 27.3% gross margin, and a valuation that had already assumed more.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
new-product mix
The whole thesis runs through one number: can Lifeway move from roughly 10% to 30% of revenue from new products by end of 2026.
calendar
q4 and full-year 2025 earnings
March 17, 2026. You want proof that the revenue mix is changing without the 27.3% gross margin cracking.
trend
share repurchase execution
The board approved up to 250,000 shares of repurchases. Follow-through matters more than the press release.
risk
core kefir dependence
About 90% of revenue still comes from the legacy drinkable kefir base. If that slows, new products need to do more than add excitement.
Analyst rankings
earnings predictability
35 / 100
A 35 / 100 score means estimates are less reliable than they are for steadier businesses. In human-speak: this is not the kind of stock where you assume the quarter will land exactly where the spreadsheet says.
source: institutional data
Institutional activity

institutional ownership data for LWAY is being compiled.

source: institutional data
source: institutional data
Price targets
3-5 year target range
n/a n/a
$24 current price
n/a target midpoint · n/a from current
target data not available

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
LWAY
xvary deep dive
lway
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it